# Zebi AI Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zebi-ai-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Total disclosed funding: $10M
- Latest round: Seed (May 1, 2019)
- Investors on record: 1

## About

Founded in 2019 and based in the US, Zebi AI Therapeutics, Inc. is a firm which develops Machine Learning programs and algorithms which provide insights into the interactions of different proteins and molecules with a view to facilitate therapeutic drug development and manufacturing. In April 2021, Relay Therapeutics, Inc., a portfolio company of BVF Partners, Casdin Capital, EcoR1 Capital, Foresite Capital, GV, Perceptive Advisors, SB Investment Advisers, Section 32 and Third Rock Ventures, acquired Zebi AI for USD 85 million. ZebiAI’s core offering is its AI-driven drug discovery platform, which integrates big data and predictive modeling to identify clinical candidate molecules. This approach enhances efficiency in early-stage research and reduces time-to-market for new drugs. The firm leverages vast experimental DNA-encoded library datasets and advanced algorithms to map the chemistry of the genome, enabling target validation and therapeutic development for unmet medical needs.

## Funding rounds

- Seed, May 1, 2019, $10M — Anterra Capital

## Investors

- Anterra Capital (https://capitalatlas.ai/funds/anterra-capital) — Seed